Search

Contact Us

Author: admin

Published by

Integral Molecular Launches Virus Neutralization Assay Services to Drive Antiviral Discovery

Researchers can now access Integral Molecular’s antibody testing expertise alongside its extensive collection of virus-like reagents including reporter viruses, VLPs, and pseudoviruses to acquire […]

Read More

Published by

Webinar Presented by Integral Molecular and The Antibody Society – Harnessing Divergent Species to Access Difficult and Conserved Antibody Targets

Thursday, April 25, 2024 8 am PT, 11 am ET, 17:00 CET View the recording To exploit highly conserved and difficult drug targets, including […]

Read More

Published by

Integral Molecular Achieves ISO 9001 Certification for its Membrane Proteome Array Service

ISO 9001 certification validates Integral Molecular’s quality processes for its Membrane Proteome Array, reflecting the company’s commitment to quality. Philadelphia – Integral Molecular, a […]

Read More

Published by

Integral Molecular Enters Into Exclusive Antibody License With Seismic Therapeutic

Philadelphia – Integral Molecular, a leading biotech company specializing in antibody discovery against undruggable protein targets, announced today that it has entered into an […]

Read More

Published by

Integral Molecular Launches TiterSafe™ Influenza Virus-Like Particles for Safe and Convenient Vaccine Testing

Philadelphia – Integral Molecular, a leading provider of reagents for vaccine evaluation, announces the launch of TiterSafe™ influenza virus-like particles, an off-the-shelf virus-alternative for […]

Read More

Published by

Integral Molecular Unveils Trispecific Molecules Targeting GPRC5D, BCMA, and CD3 for Multiple Myeloma

Philadelphia – Integral Molecular, a leading biotech company specializing in antibody discovery against undruggable protein targets will present multispecific molecules targeting GPRC5D, BCMA, and […]

Read More

Published by

Integral Molecular Secures Nearly $900K in NIH Funding to Discover Antibodies Against Difficult and Conserved Protein Targets

PHILADELPHIA–Integral Molecular, a leading biotech company specializing in antibody discovery against challenging protein targets, announces that it has been awarded NIH funding totaling $896,000. […]

Read More

Published by

Webinar presented by Integral Molecular and Fierce Biotech – Innovative Research Tools to Combat Biological Threats

Thursday, October 12, 2023 8 am PT, 11 am ET, 17:00 CET View the recording A fundamental research question continues to resonate today: How […]

Read More

Published by

Webinar presented by Integral Molecular and Fierce Biotech – Conquering Undruggable Targets to Obtain Preclinical Antibodies

Thursday, September 14, 2023 8 am PT, 11 am ET, 17:00 CET Watch the webinar Despite the remarkable growth of antibody-based therapies in recent […]

Read More

Search